Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T22583 | ||||
Target Name | Sodium/glucose cotransporter 2 | ||||
Synonyms | Low affinity sodium-glucose cotransporter; Na(+)/glucose cotransporter 2; SGLT2; Sodium dependent glucose transporter2; SLC5A4 | ||||
Target Type | Clinical Trial | ||||
Gene Name | SLC5A2 | ||||
Biochemical Class | Solute:sodium symporter | ||||
UniProt ID | SC5A2_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Type 2 diabetes | ||||
Example drug | RG7201 | Phase 3 | [532723], [1572592] | ||
Tissue | Liver tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.09 Z-score: -0.37 P-value: 3.26E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
Reference | |||||
Ref 532723 | Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.